Maintenance alemtuzumab in refractory chronic lymphocytic leukaemia.

Trial Profile

Maintenance alemtuzumab in refractory chronic lymphocytic leukaemia.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2016

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Feb 2010 Actual number of patients (12) added as reported by ClinicalTrials.gov record.
    • 19 Feb 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 11 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top